Sugi Predict

Sugi Predict / Targets / USP7

USP7

Ubiquitin carboxyl-terminal hydrolase 7 · Q93009 · USP7 on Sugi Atlas →

40,782 patent compounds predicted against USP7, 25,390 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL440463 SCHEMBL440463 0.50 11/20
SCHEMBL624413 SCHEMBL624413 0.69 10/20
SCHEMBL624668 SCHEMBL624668 0.55 10/20
SCHEMBL603522 SCHEMBL603522 0.41 10/20
SCHEMBL247903 SCHEMBL247903 0.49 7/20
SCHEMBL623725 SCHEMBL623725 0.69 6/20
SCHEMBL752682 SCHEMBL752682 0.50 6/20
SCHEMBL487830 SCHEMBL487830 0.50 5/20
SCHEMBL487592 SCHEMBL487592 0.49 5/20
Oleanolic_Acid Oleanolic_Acid (SCHEMBL408433) 0.86 4/20
SCHEMBL752298 SCHEMBL752298 0.52 4/20
SCHEMBL487657 SCHEMBL487657 0.52 4/20
SCHEMBL487901 SCHEMBL487901 0.47 4/20
SCHEMBL947308 SCHEMBL947308 0.46 4/20
SCHEMBL488005 SCHEMBL488005 0.44 4/20
SCHEMBL613682 SCHEMBL613682 0.40 4/20
Oleanolic_Acid Oleanolic_Acid (SCHEMBL71070) 1.00 3/20
Hederagenin Hederagenin (SCHEMBL359809) 1.00 3/20
Oleanolic_Acid Oleanolic_Acid (SCHEMBL741472) 1.00 3/20
Oleanolic_Acid Oleanolic_Acid (SCHEMBL741473) 1.00 3/20

Clinical trials — most relevant to USP7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer PHASE1/PHASE2COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Autophagy Bladder Cancer nanUNKNOWN
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in MYO7A nanRECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being nanUNKNOWN
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma nanCOMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment nanUNKNOWN
New Signaling Pathway Targeting Systemic Lupus Erythematosus nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP7 binder may also engage these)

ProteinNameSimilarity
Q4VSI4 — 1.000 Q4VSI4 →
Q6U7I1 — 1.000 Q6U7I1 →
Q6A4J8 — 1.000 Q6A4J8 →
Q09879 — 0.997 Q09879 →
Q9UTT1 — 0.996 Q9UTT1 →
Q9VYQ8 — 0.994 Q9VYQ8 →
Q9FPT1 — 0.992 Q9FPT1 →
Q84WU2 — 0.992 Q84WU2 →
E1BMF7 — 0.991 E1BMF7 →
USP13 Ubiquitin carboxyl-terminal hydrolase 13 0.988 landscape →
Q9Y4E8 — 0.988 Q9Y4E8 →
B2GUZ1 — 0.988 B2GUZ1 →
Q5BKP2 — 0.987 Q5BKP2 →
Q2HJE4 — 0.987 Q2HJE4 →
USP4 Ubiquitin carboxyl-terminal hydrolase 4 0.987 landscape →
A6QR55 — 0.987 A6QR55 →
Q9JMA1 — 0.987 Q9JMA1 →
P40826 — 0.987 P40826 →
O02697 — 0.986 O02697 →
Q5RCD3 — 0.986 Q5RCD3 →
A1DFN6 — 0.986 A1DFN6 →
F6Z5C0 — 0.986 F6Z5C0 →
F1QFS9 — 0.986 F1QFS9 →
P50101 — 0.985 P50101 →
A0A0G2K344 — 0.985 A0A0G2K344 →
P35123 — 0.985 P35123 →
PIK3CA Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 0.985 landscape →
P32871 — 0.985 P32871 →
Q8BTI9 — 0.985 Q8BTI9 →
Q8R5H1 — 0.985 Q8R5H1 →